Aaron Boster

And a medicine like Ampira can buttress against that.

Or use the example of gabapentin, Neurontin.

This is a medicine invented to treat seizures, but it's used ubiquitously to treat neuropathic pain.

MS is a very painful condition and people can have a limb that looks normal, but it's burning.

And so we can use the symptomatic medicine to make that better.

There's a third category of medicine, which really is what I was talking about, which we call disease-modifying therapies.

And these are medicines that literally change the disease course.

They change the trajectory.

They decrease attacks.

They decrease the new spots on the brain.

And they slow the accumulation of disability.

We used an example of Ocrevus, which is probably the most utilized medicine in the world to treat MS.

And it's the only medicine that can treat both relapsing and primary progressive forms of MS.

I'll tell you just a quick story.

I was involved in the Oakervis trials and it was 2017.

We had sort of like a sense of the results, but I paid a lot of money to fly to the big international meeting in Barcelona, Spain.

And I sat in the audience and I cried like a little kid as they presented the PPMS data, because this was the very first time in the history of the universe that we did it.

We finally were able to impact primary progressive MS.

You know, many of us have spent clinical trial after clinical trial after clinical trial failing at cracking that nut.

And here we finally did it.